21 completed, 6 unknown, 2 not yet recruiting, 2 terminated. 34 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 34 | Completed 21, Unknown 6, Not yet recruiting 2, Terminated 2, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Unknown 2 |
| Phase 3 | 1 | Unknown 1 |
Follow Osteoporosis, Postmenopausal: new trials by email Literature Review of Osteoporosis, Postmenopausal trials Research Report on Osteoporosis, Postmenopausal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of TST002 Injection in Postmenopausal Women With Osteoporosis or Low Bone Mass Denosumab, Placebo - Postmenopausal Osteoporosis, Low Bone Mass | Phase 2 | Not yet recruiting | Transcenta Therapeutics (Hangzhou) Co., Ltd. | 110 | 2026-10-31 | 2026-09-11 |
| Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes Romosozumab, Alendronate (Fosamax), Placebo Romosozumab - Osteoporosis, Post-menopausal | Phase 2 | Withdrawn | University of Pittsburgh | 2026-06-20 | 2026-06-04 | |
| COMPASS - COpenhagen MenoPAuSe Study Triptorelin 11.25 mg, Sodium Chloride 0.9%, Estradiol (E2) - Menopausal Osteoporosis, Bone Markers | Phase 2 | Recruiting | Martin Blomberg Jensen | 192 | 2025-10-02 | 2026-03-02 |
| Efficacy of OsteoBor in Postmenopausal Osteoporosis Sodium pentaborate pentahydrate - Osteoporosis, Postmenopausal | Phase 2 | Not yet recruiting | Tabriz University of Medical Sciences | 30 | 2025-03-01 | 2025-02-05 |
| A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) AGA2118, Placebo - Postmenopausal Osteoporosis | Phase 2 | Active not recruiting | Angitia Biopharmaceuticals | 379 | 2024-10-31 | 2026-02-10 |
| MAGnesium Effect With ANtiosteoporotic Drugs Follow-up of patients with postmenopausal osteoporosis, with or without fractures, requiring initiation of injectable bisphosphonate therapy as part of their usual care, Follow-up of patients with postmenopausal osteoporosis, fractured or not, requiring initiation of injectable bisphosphonate therapy as part of care with magnesium supplementation - Osteoporosis, Postmenopausal | Phase 2 | Completed | University Hospital, Clermont-Ferrand | 45 | 2022-06-28 | 2024-12-27 |
| Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis JMT103, Denosumab, Placebo - Postmenopausal Osteoporosis | Phase 2 | Unknown | Shanghai JMT-Bio Inc. | 200 | 2022-04-21 | 2022-07-18 |
| Effect of GLP-1 Receptor Agonists on Trabecular Bone Score GLP-1 receptor agonist - Osteoporosis, Postmenopausal, Diabetes Mellitus, Type 2 | Phase 2 | Terminated | University of Mississippi Medical Center | 5 | 2021-11-09 | 2025-06-13 |
| Coral Calcium's Effect on Bone Density in Postmenopausal Women With and Without Ibandronate Coral Complex 3, Ibandronate, Vitamin D3 - Osteoporosis, Postmenopausal | Phase 2 | Completed | Columbia University | 60 | 2020-02-05 | 2024-05-09 |
| G56W1 in Women With Postmenopausal Osteoporosis rhPTH（1-34） 28.2μg, rhPTH（1-34） 56.5μg, teriparatide acetate(Teribone™) - Postmenopausal Osteoporosis | Phase 1 / Phase 2 | Unknown | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 148 | 2018-10-01 | 2018-10-25 |
| The Deferasirox-calcium-vitamin D3 Therapy for Postmenopausal Osteoporosis (PMOP) Deferasirox and calcium-vitamin D3, Calcium-vitamin D3 - Postmenopausal Osteoporosis | Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 10 | 2018-01-15 | 2018-05-17 |
| Effect of VSL#3 on Bone Mineral Density in Postmenopausal Women VSL#3, Placebo - Menopausal Osteoporosis | Phase 2 | Terminated | Emory University | 35 | 2017-10-01 | 2020-03-04 |
| Effect of Blueberries on Bone Turnover Blueberry Baseline, Blueberry Low, Blueberry Medium - Osteoporosis, Postmenopausal, Bone Loss, Age-related | Phase 1 / Phase 2 | Unknown | Purdue University | 20 | 2017-01-12 | 2018-05-07 |
| Vitamin K as Additive Treatment in Osteoporosis Phylloquinone, Menatetrenone (MK4), placebo - Post-menopausal Osteoporosis | Phase 2 / Phase 3 | Unknown | Guy's and St Thomas' NHS Foundation Trust | 105 | 2015-04-01 | 2020-02-13 |
| Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis Romosozumab, Placebo - Postmenopausal Osteoporosis (PMO) | Phase 2 | Completed | Amgen | 252 | 2012-10-12 | 2019-03-25 |
| Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis Abaloparatide Transdermal (50 mcg), Abaloparatide Transdermal (100 mcg), Abaloparatide Transdermal (150 mcg) - Post Menopausal Osteoporosis | Phase 2 | Completed | Radius Health, Inc. | 250 | 2012-09-25 | 2020-06-16 |
| Molecular Mechanism of POP Kidney Yin Deficiency Syndrome From the Interventional Effects of CLCF1 Liuwei Dihuang Pills - Postmenopausal Osteoporosis | Phase 2 | Unknown | Fujian Academy of Traditional Chinese Medicine | 25 | 2012-01-01 | 2013-04-18 |
| Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women PTH analog, Placebo, Forsteo (Teriparatide) - Postmenopausal Osteoporosis | Phase 2 | Completed | Unigene Laboratories Inc. | 97 | 2011-02-01 | 2013-03-01 |
| A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis Oral calcitonin at dinnertime, Oral placebo at dinnertime, Oral calcitonin at bedtime - Osteopenia | Phase 2 | Completed | Tarsa Therapeutics, Inc. | 129 | 2011-01-01 | 2014-09-12 |
| MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012) MK-5442, Placebo to MK-5442, Alendronate Sodium - Osteoporosis, Postmenopausal Osteoporosis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 526 | 2009-11-01 | 2016-01-22 |
Showing 20 of 34. Sign in to see all of them.
Osteoporosis (15) · Bone Diseases, Metabolic (5) · Bone Diseases (3) · Musculoskeletal Diseases (2) · Bone Resorption (1) · Breast Neoplasms (1) · Crisponi syndrome (1) · Diabetes Mellitus, Type 2 (1) · Hot Flashes (1) · Sclerosteosis (1)
Metabolic Diseases (34) · Nutritional and Metabolic Diseases (34) · Musculoskeletal Diseases (32) · Bone Diseases (31) · Bone Diseases, Metabolic (29) · Osteoporosis (19) · Breast Diseases (1) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Neoplasms (1) · Neoplasms by Site (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Skin Diseases (1)
Alendronate (5) · Denosumab (4) · Cholecalciferol (3) · romosozumab (3) · Calcium Carbonate (2) · Ibandronic Acid (2) · Risedronic Acid (2) · Teriparatide (2) · 3-(6-methoxypyridin-3-yl)-3-(2-oxo-3-(3-(5,6,7,8-tetrahydro(1,8)naphthyridin-2-yl)propyl)imidazolidin-1-yl)propionic acid (1) · Deferasirox (1) · Estradiol (1) · JTT 305 (1) · Nuclear Receptor Subfamily 4, Group A, Member 2 (1) · Parathyroid Hormone (1) · Sodium Chloride (1)
Amgen (4) · Merck Sharp & Dohme LLC (3) · Angitia Biopharmaceuticals (1) · Columbia University (1) · Dana-Farber Cancer Institute (1) · Emory University (1) · Fujian Academy of Traditional Chinese Medicine (1) · Guy's and St Thomas' NHS Foundation Trust (1) · Martin Blomberg Jensen (1) · Massachusetts General Hospital (1) · National Center for Complementary and Integrative Health (NCCIH) (1) · Purdue University (1) · Radius Health, Inc. (1) · Sanofi (1) · Second Affiliated Hospital of Soochow University (1)
United States (12) · China (4) · Denmark (3) · Estonia (2) · Poland (2) · United Kingdom (2) · Argentina (1) · Armenia (1) · France (1) · Japan (1) · Norway (1) · Ukraine (1)
Angela Rogers, Dr (1) · Bettina S Nedergaard, MD (1) · Chantell Wilson, PhD (1) · Christence S Teglbjaerg, MD (1) · Connie M Weaver, PhD (1) · David S. Krause, MD (1) · Dr. Fredi Kronenberg (1) · Eugene McCloskey, Dr (1) · Geeta Hampson, MD (1) · Ivo Valter, MD (1) · Joel S. Finkelstein, MD (1) · John P Bilezikian, MD, PhD (1)
PMID 20839291, PMID 21111078, PMID 23234813, PMID 23719683, PMID 24382002, PMID 26556736, PMID 30638769, PMID 33606045, PMID 34530172, PMID 37269909, PMID 37338608, PMID 40686685, PMID 41566091
2008 (1), 2009 (1), 2025 (1), P50AR044855 (1), P50AT000090 (1)